Skip to main content

Peptide Therapeutic Deal Benchmarks in Immunology & Autoimmune

Median Upfront
$490M
Range: $260M - $709M
Total Deal Value
$2.6B
Range: $1.6B - $3.5B
Royalty Rate
13.3% - 22.2%
Tiered up to 26.2%
Dev Milestones
$413M
Range: $265M - $563M
Model Your Deal

Market Analysis

Peptide Therapeutic therapies in immunology & autoimmune have seen significant M&A and licensing activity in recent years. Based on analysis of 1,500+ verified transactions, the median upfront payment for a Phase 2 peptide therapeutic asset in immunology & autoimmune is $490M, with total deal values reaching $2.6B. Development milestones average $413M, while regulatory milestones contribute $722M.

The immunology & autoimmune peptide therapeutic landscape is characterized by high competitive intensity, particularly in inflammatory bowel disease and autoimmune conditions. CAR-T for autoimmune diseases, TL1A inhibitors, and next-generation targeted therapies are reshaping the licensing landscape. The recommended deal structure allocates approximately 19% to upfront payments and 81% to milestones, reflecting the risk-reward profile at the Phase 2 stage.

Royalty rates for peptide therapeutic immunology & autoimmune deals range from 13.3% to 22.2% at the base tier, with tiered escalation reaching 17.3%-26.2% on blockbuster sales. Commercial milestones averaging $928M further reward successful market penetration.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the typical upfront for a peptide therapeutic immunology & autoimmune licensing deal?
Based on our analysis, Phase 2 peptide therapeutic licensing deals in immunology & autoimmune average $490M in upfront payments, with a range of $260M to $709M depending on data quality, competitive positioning, and territorial scope.
What is the total deal value for peptide therapeutic immunology & autoimmune transactions?
The median total deal value for Phase 2 peptide therapeutic assets in immunology & autoimmune is $2.6B, ranging from $1.6B to $3.5B. This includes development milestones ($413M), regulatory milestones ($722M), and commercial milestones ($928M).
What royalty rates are standard for peptide therapeutic deals in immunology & autoimmune?
Base royalty rates for peptide therapeutic immunology & autoimmune transactions range from 13.3% to 22.2%, with tiered escalations reaching 17.3%-26.2% on peak sales. Rates are influenced by mechanism differentiation, competitive landscape, and territorial scope.
How are milestones structured in peptide therapeutic immunology & autoimmune deals?
Peptide Therapeutic immunology & autoimmune deals allocate approximately 81% of total deal value to milestones. Development milestones ($413M) make up the largest share, followed by commercial milestones ($928M) and regulatory milestones ($722M).
PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Related Benchmarks

Small Molecule in Immunology & Autoimmune

View

Monoclonal Antibody in Immunology & Autoimmune

View

Peptide Therapeutic in Oncology

View

Peptide Therapeutic in Neurology

View

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.

Start Calculating
For Funds & Advisors

Need the full deal landscape?

The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.

Configure Brief — $2,500All-inclusive · White-label · Walkthrough included